四環醫藥(0460.HK)大漲超18% 獨家代理樂提葆獲批於中國市場推出
格隆匯2月16日丨四環醫藥(0460.HK)今日股價大漲,現漲幅為18.42%,報2.7港元,成交額超4億港元,總市值超225億港元。四環醫藥2月10日公佈,由公司獨家代理並由韓國生物製藥公司Hugel生產的注射用A型肉毒毒素素Letybo 50U(樂提葆),於當日正式獲中國國家藥品監督管理局批准於市場推出。樂提葆為第四個獲准在中國市場推出的A型肉毒毒素,也是韓國同類產品中的首個。國泰君安香港表示,中國肉毒毒素產品2019年的市場規模約為人民幣40億元,預計2025年將達到115億元人民幣,複合年均增長率約達19%;預計未來三年,樂提葆將佔肉毒桿菌毒素產品約30%的市場份額。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.